RAPPORT THERAPEUTICS INC (RAPP) Stock Price, Quote, News and Overview
NASDAQ:RAPP - Nasdaq - US75383L1026 - Currency: USD
RAPP Quote, Performance and Key Statistics
NASDAQ:RAPP (3/5/2025, 2:05:34 PM)
10.09
+0.1 (+1%)
The current stock price of RAPP is 10.09 USD. In the past month the price decreased by -39.82%.
RAPP Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 70.96 | 875.77B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 28.06 | 403.55B | ||
| JNJ | JOHNSON & JOHNSON | 16.55 | 397.98B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 21.62 | 242.70B | ||
| MRK | MERCK & CO. INC. | 12.16 | 235.08B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.17 | 222.20B | ||
| SNY | SANOFI-ADR | 14.6 | 148.30B | ||
| PFE | PFIZER INC | 8.33 | 146.80B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 52.81 | 122.11B | ||
| GSK | GSK PLC-SPON ADR | 8.17 | 79.20B | ||
| ZTS | ZOETIS INC | 28.44 | 75.96B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 34.22 | 47.73B |
Related stock screener links
About RAPP
Company Profile
Rapport Therapeutics Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Boston, Massachusetts and currently employs 58 full-time employees. The company went IPO on 2024-06-07. Rapport Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the discovery and development of a portfolio of precision small molecule product candidates. The firm focuses on developing a new class of precision neuromedicines aimed at providing patients with alternatives to existing treatments for central nervous system disorders. The company advances a pipeline of therapeutic programs to patients living with central nervous system (CNS) disorders, including focal onset epilepsy, pain, bipolar disorder, and hearing disorders. Its program ionotropic receptors for glutamate (iGluR) are ligand gated ion channels activated by the neurotransmitter glutamate. Its RAP-219 is a clinical-stage small molecule designed to achieve neuroanatomical specificity through its selective targeting of a RAP known as TARPy8, which is associated with the neuronal AMPAR, a clinically validated target for epilepsy.
Company Info
RAPPORT THERAPEUTICS INC
1325 Boylston Street, Suite 401
Boston MASSACHUSETTS US
Employees: 58
Company Website: https://www.rapportrx.com/
Phone: 8573218020
RAPPORT THERAPEUTICS INC / RAPP FAQ
What is the stock price of RAPPORT THERAPEUTICS INC today?
The current stock price of RAPP is 10.09 USD. The price increased by 1% in the last trading session.
What is the ticker symbol for RAPPORT THERAPEUTICS INC stock?
The exchange symbol of RAPPORT THERAPEUTICS INC is RAPP and it is listed on the Nasdaq exchange.
On which exchange is RAPP stock listed?
RAPP stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for RAPPORT THERAPEUTICS INC stock?
10 analysts have analysed RAPP and the average price target is 38.08 USD. This implies a price increase of 277.4% is expected in the next year compared to the current price of 10.09. Check the RAPPORT THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is RAPPORT THERAPEUTICS INC worth?
RAPPORT THERAPEUTICS INC (RAPP) has a market capitalization of 369.09M USD. This makes RAPP a Small Cap stock.
How many employees does RAPPORT THERAPEUTICS INC have?
RAPPORT THERAPEUTICS INC (RAPP) currently has 58 employees.
What are the support and resistance levels for RAPPORT THERAPEUTICS INC (RAPP) stock?
RAPPORT THERAPEUTICS INC (RAPP) has a resistance level at 14.83. Check the full technical report for a detailed analysis of RAPP support and resistance levels.
Should I buy RAPPORT THERAPEUTICS INC (RAPP) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of RAPP, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of RAPP, evaluating the profitability, health, valuation and growth aspects
- RAPPORT THERAPEUTICS INC (RAPP) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- RAPPORT THERAPEUTICS INC (RAPP) Sales and EPS estimates to see what analysts future expectations are.
- RAPPORT THERAPEUTICS INC (RAPP) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- RAPPORT THERAPEUTICS INC (RAPP) Insider and Institutional Ownership to learn about the owners and their transactions.
- RAPPORT THERAPEUTICS INC (RAPP) Stock Chart to make your own analysis
- RAPPORT THERAPEUTICS INC (RAPP) Latest news and press-releases to stay up to date.
Does RAPPORT THERAPEUTICS INC (RAPP) stock pay dividends?
RAPP does not pay a dividend.
What is the Price/Earnings (PE) ratio of RAPPORT THERAPEUTICS INC (RAPP)?
RAPPORT THERAPEUTICS INC (RAPP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.62).
What is the Short Interest ratio of RAPPORT THERAPEUTICS INC (RAPP) stock?
The outstanding short interest for RAPPORT THERAPEUTICS INC (RAPP) is 4.97% of its float. Check the ownership tab for more information on the RAPP short interest.
RAPP Technical Analysis
RAPP Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to RAPP. While RAPP has a great health rating, there are worries on its profitability.
RAPP Financial Highlights
Over the last trailing twelve months RAPP reported a non-GAAP Earnings per Share(EPS) of -2.62. The EPS decreased by -226.57% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -28.12% | ||
| ROE | -28.82% | ||
| Debt/Equity | 0 |
RAPP Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to RAPP. The Buy consensus is the average rating of analysts ratings from 10 analysts.